cyclic adenosine-5'-trimetaphosphate (ATMP)

structure given in first source, cyclic refers to arrangement of three phosphates

Also Known As:

ATMP; CATMP; adenosine, 5'-O-(4,6-dihydroxy-1,3,5,2,4,6-trioxaariphosphorinan-2-yl)-, P,P',P''-trioxide; adenosine, 5'-O-(4,6-dihydroxy-1,3,5,2,4,6-trioxotriphosphorinan-2-yl)-, P,P',P''-trioxide; adenosine-5'-trimetaphosphate; monoadenosine 5'-trimetaphosphate; Adenosine, 5'-O-(4,6-dihydroxy-1,3,5,2,4,6-trioxatriphosphorinan-2-yl)-, P,P',P''-trioxide

Networked: 36 relevant articles (4 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Calvo, Gonzalo: 2 articles (01/2022 - 10/2021)
2.	Juan, Manel: 2 articles (01/2022 - 10/2021)
3.	Trias, Esteve: 2 articles (01/2022 - 10/2021)
4.	MacLoughlin, Ronan: 2 articles (09/2020 - 09/2020)
5.	Galli, Maria Cristina: 2 articles (01/2016 - 01/2011)
6.	Lo Cicero, Viviana: 2 articles (09/2014 - 09/2009)
7.	Moccetti, Tiziano: 2 articles (09/2014 - 09/2009)
8.	Soncin, Sabrina: 2 articles (09/2014 - 09/2009)
9.	Sürder, Daniel: 2 articles (09/2014 - 09/2009)
10.	Calderón, Hugo: 1 article (01/2022)

Related Diseases

1.	Chronic Disease (Chronic Diseases) 01/01/2020 - "Fear of adverse events as part of threat appraisal was the predominant consideration for parents in considering whether to enroll their child living with a manageable, chronic condition in a pediatric clinical trial of an ATMP. " 01/01/2021 - "Advanced Therapy Medicinal Products (ATMP) provide promising treatment options particularly for unmet clinical needs, such as progressive and chronic diseases where currently no satisfying treatment exists. "
2.	Porphyrias (Porphyria) 01/01/1993 - "Two inhibitors of liver cytochrome P450, compound SKF 525-A and piperonyl butoxide, when given before ATMP, afforded protection against ATMP-induced porphyria and production of N-methyl protoporphyrin, suggesting a role of cytochrome P450 in the induction of the metabolic disorder. "
3.	Melanoma (Melanoma, Malignant) 11/01/2018 - "Tumor-infiltrating lymphocytes (TIL)-therapy in advanced melanoma is an advanced therapy medicinal product (ATMP) which, despite promising results, has not been implemented widely. "
4.	Body Weight (Weight, Body) 01/01/2021 - "In contrast, serum insulin levels, glucose tolerance and body weight improved considerably in the high and medium-dose ATMP and metformin groups. "
5.	Neoplasms (Cancer) 01/01/2019 - "Evaluation of the tumor microenvironment in MPE demonstrated notable reductions in tumor cells and CD163+ macrophages in MPE after ATMP-MTX infusion, which then translated into objective clinical responses. " 01/01/2011 - "ATMP development opens novel avenues for therapeutic approaches in numerous diseases, including cancer and neurodegenerative and cardiovascular diseases. " 01/01/2016 - "This chapter discusses European regulatory requirements for development of advanced therapy medicinal products (ATMP) for cancer immunotherapy approaches, describing the framework for clinical trials and for marketing authorization.Regulatory" 01/01/2011 - "Advanced therapy medicinal products (ATMP) can offer new, effective therapeutic options for the treatment of severe illnesses, including cancer, neurodegenerative and cardiovascular diseases. " 12/01/2022 - "Over the past years, an increasing number of ATMP entered the market for treatment of cancer, genetic disorders, skeletal defects and metabolic diseases. "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Piperonyl Butoxide
3.	Metformin (Glucophage)
4.	Insulin (Novolin)
5.	Cytochrome P-450 Enzyme System (Cytochrome P450)
6.	protoporphyrin IX
7.	Lactic Acid (Lactate)
8.	Protein Kinases (Protein Kinase)
9.	Nitrogen
10.	Ions

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Conservative Treatment
4.	Cell- and Tissue-Based Therapy (Cell Therapy)
5.	Investigational Therapies (Experimental Therapy)